PE89199A1 - Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes - Google Patents

Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes

Info

Publication number: PE89199A1
Authority: PE; Peru
Prior art keywords: treatment; diabetes; tiazolidinadiona; pharmaceutical composition; glucosidase inhibitor
Prior art date: 1997-06-18

Application number

PE1998000536A

Other languages

English (en)

Spanish (es)

Inventor

Stephen Alistair Smith

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-18

Filing date

1998-06-18

Publication date

1999-10-23

1997-06-18 Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en

1998-03-27 Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en

1998-06-18 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1999-10-23 Publication of PE89199A1 publication Critical patent/PE89199A1/es

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 3
229940077274 Alpha glucosidase inhibitor Drugs 0.000 title 1
239000003888 alpha glucosidase inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract 1
-1 AMINO Chemical class 0.000 abstract 1
229940122355 Insulin sensitizer Drugs 0.000 abstract 1
102100024295 Maltase-glucoamylase Human genes 0.000 abstract 1
IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 abstract 1
229960002632 acarbose Drugs 0.000 abstract 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract 1
108010028144 alpha-Glucosidases Proteins 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 abstract 1
229950000269 emiglitate Drugs 0.000 abstract 1
NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 abstract 1
229960001110 miglitol Drugs 0.000 abstract 1
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Fodder In General (AREA)

PE1998000536A 1997-06-18 1998-06-18 Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes PE89199A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9712865.6A GB9712865D0 (en)	1997-06-18	1997-06-18	Novel method of treatment
GBGB9806708.5A GB9806708D0 (en)	1998-03-27	1998-03-27	Novel method

Publications (1)

Publication Number	Publication Date
PE89199A1 true PE89199A1 (es)	1999-10-23

Family

ID=26311746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE1998000536A PE89199A1 (es)	1997-06-18	1998-06-18	Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes

Country Status (24)

Country	Link
EP (1)	EP0975343A1 (fr)
JP (1)	JP2001523271A (fr)
KR (1)	KR20010013845A (fr)
CN (1)	CN1274282A (fr)
AP (1)	AP9901720A0 (fr)
AR (2)	AR014881A1 (fr)
AU (1)	AU8799998A (fr)
BG (1)	BG103966A (fr)
BR (1)	BR9810186A (fr)
CA (1)	CA2294134A1 (fr)
CO (1)	CO4940453A1 (fr)
DZ (1)	DZ2519A1 (fr)
EA (1)	EA200000040A1 (fr)
IL (1)	IL133138A0 (fr)
MA (1)	MA26510A1 (fr)
NO (1)	NO996270L (fr)
NZ (1)	NZ501345A (fr)
OA (1)	OA11631A (fr)
PE (1)	PE89199A1 (fr)
PL (1)	PL337577A1 (fr)
SK (1)	SK179499A3 (fr)
TR (1)	TR199903072T2 (fr)
UY (1)	UY25051A1 (fr)
WO (1)	WO1998057635A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
HRP20010773B1 (en)	1999-04-23	2005-06-30	Smithkline Beecham P.L.C.	Thiazolidinedione derivative and its use as antidiabetic
US20030045553A1 (en)	2001-04-04	2003-03-06	Bussolari Jacqueline C.	Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
JP4590158B2 (ja)	2001-04-04	2010-12-01	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
FR2832930A1 (fr) *	2001-12-03	2003-06-06	Lipha	Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) *	2002-08-06	2004-03-04	Yaizu Suisankagaku Industry Co Ltd	糖尿病治療薬効果促進剤
CN101121004B (zh) *	2006-08-08	2010-07-21	鲁南制药集团股份有限公司	含有胰岛素增敏剂和米格列醇的药物组合物
CN101584705B (zh) *	2008-05-24	2010-10-27	鲁南制药集团股份有限公司	一种治疗糖尿病及其并发症的药物组合物
CN101584688B (zh) *	2008-05-24	2010-11-10	鲁南制药集团股份有限公司	一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06510286A (ja) *	1991-08-26	1994-11-17	ファルマシア・アンド・アップジョン・カンパニー	３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
US5917052A (en) *	1994-09-28	1999-06-29	Shaman Pharmaceuticals, Inc.	Hypoglycemic agent from cryptolepis
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes

1998
- 1998-06-15 WO PCT/EP1998/003691 patent/WO1998057635A1/fr not_active Ceased
- 1998-06-15 PL PL98337577A patent/PL337577A1/xx unknown
- 1998-06-15 JP JP50375699A patent/JP2001523271A/ja not_active Ceased
- 1998-06-15 AP APAP/P/1999/001720A patent/AP9901720A0/en unknown
- 1998-06-15 AU AU87999/98A patent/AU8799998A/en not_active Abandoned
- 1998-06-15 CN CN98806319A patent/CN1274282A/zh active Pending
- 1998-06-15 EA EA200000040A patent/EA200000040A1/ru unknown
- 1998-06-15 EP EP98939513A patent/EP0975343A1/fr not_active Withdrawn
- 1998-06-15 SK SK1794-99A patent/SK179499A3/sk unknown
- 1998-06-15 KR KR1019997011866A patent/KR20010013845A/ko not_active Withdrawn
- 1998-06-15 IL IL13313898A patent/IL133138A0/xx unknown
- 1998-06-15 BR BR9810186-2A patent/BR9810186A/pt not_active IP Right Cessation
- 1998-06-15 TR TR1999/03072T patent/TR199903072T2/xx unknown
- 1998-06-15 CA CA002294134A patent/CA2294134A1/fr not_active Abandoned
- 1998-06-17 MA MA25121A patent/MA26510A1/fr unknown
- 1998-06-17 AR ARP980102885A patent/AR014881A1/es unknown
- 1998-06-17 AR ARP980102882A patent/AR013352A1/es unknown
- 1998-06-17 DZ DZ980129A patent/DZ2519A1/fr active
- 1998-06-18 CO CO98034648A patent/CO4940453A1/es unknown
- 1998-06-18 UY UY25051A patent/UY25051A1/es not_active Application Discontinuation
- 1998-06-18 PE PE1998000536A patent/PE89199A1/es not_active Application Discontinuation
- 1998-07-15 NZ NZ501345A patent/NZ501345A/en unknown
1999
- 1999-12-08 BG BG103966A patent/BG103966A/bg unknown
- 1999-12-17 OA OA9900295A patent/OA11631A/en unknown
- 1999-12-17 NO NO996270A patent/NO996270L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2001523271A (ja)	2001-11-20
WO1998057635A1 (fr)	1998-12-23
UY25051A1 (es)	2000-09-29
KR20010013845A (ko)	2001-02-26
NO996270D0 (no)	1999-12-17
SK179499A3 (en)	2000-11-07
CO4940453A1 (es)	2000-07-24
AR014881A1 (es)	2001-04-11
PL337577A1 (en)	2000-08-28
MA26510A1 (fr)	2004-12-20
OA11631A (en)	2004-11-22
EA200000040A1 (ru)	2000-08-28
IL133138A0 (en)	2001-03-19
CA2294134A1 (fr)	1998-12-23
NZ501345A (en)	2001-10-26
EP0975343A1 (fr)	2000-02-02
BR9810186A (pt)	2000-08-08
TR199903072T2 (xx)	2000-07-21
AR013352A1 (es)	2000-12-27
AU8799998A (en)	1999-01-04
BG103966A (bg)	2000-07-31
AP9901720A0 (en)	1999-12-31
DZ2519A1 (fr)	2003-02-01
NO996270L (no)	1999-12-17
CN1274282A (zh)	2000-11-22

Legal Events

Date	Code	Title	Description
2002-07-17	FC	Refusal

Publication	Publication Date	Title
PE83199A1 (es)	1999-10-22	Composicion farmaceutica de tiazolidinadiona y biguanida para el tratamiento de la diabetes
UY25713A1 (es)	2001-08-27	Método para tratar diabetes empleando un inhibidor ap2 y combinación.
TR200102874T2 (tr)	2002-03-21	Heterosiklik ierikli bifenil AP2 nleyicileri ve metot.
PE99599A1 (es)	1999-12-18	Composicion farmaceutica para el tratamiento de la diabetes
BR9714505A (pt)	2000-03-21	para o diabetes.
AR017819A1 (es)	2001-10-24	Sales de metformina, las composiciones farmaceuticas que las contienen, los metodos terapeuticos que aplican dichos compuestos y las combinaciones de talescompuestos con otros agentes terapeuticos
AR057970A2 (es)	2007-12-26	Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
FI925522A0 (fi)	1992-12-04	Menetelmä hypoglykeemisten ja hypokolesteroleemisten oksa- ja tiatsolidiinidionien valmistamiseksi
PE104499A1 (es)	2000-01-13	Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes
AR046210A1 (es)	2005-11-30	Preparacion solida
PE99499A1 (es)	1999-12-18	Composicion farmaceutica para el tratamiento de la diabetes
ES2142388T3 (es)	2000-04-16	Agente anti-diabetico.
PE99799A1 (es)	1999-12-22	Composicion farmaceutica para el tratamiento de la diabetes
PE108199A1 (es)	2000-01-14	Composicion farmaceutica de tiazolidindiona y sulfonilurea
UY25051A1 (es)	2000-09-29	Composiciones para el tratamiento de diabetes mellitus
EA200300005A1 (ru)	2003-04-24	Соль тиазолидиндиона для лечения сахарного диабета
CY1107767T1 (el)	2013-04-18	Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο
CO5150180A1 (es)	2002-04-29	Nueva composicion y uso liberacion modificada
ECSP982591A (es)	1999-02-22	Nuevo metodo de tratamiento iv
ECSP982592A (es)	1999-02-22	Nuevo metodo de tratamiento v
ECSP982535A (es)	1999-04-13	Nuevo metodo de tratamiento (i)
ECSP982593A (es)	1999-02-22	Nuevo metodo de tratamiento vi
ES2174748B1 (es)	2003-09-16	Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
ECSP982542A (es)	1999-02-11	Nuevo metodo de tratamiento iii
ECSP982534A (es)	1999-02-11	Nuevo metodo de tratamiento